Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephanie M de Boer

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
The American Journal of Cardiology|November 9, 2010
Impact of clinical presentation and pretest likelihood on the relation between calcium score and computed tomographic coronary angiographyJacob M van Werkhoven, Stephanie M de Boer, Joanne D Schuijf, et al.
The International Journal of Cardiovascular Imaging|May 12, 2012
Non-invasive computed tomography coronary angiography as a gatekeeper for invasive coronary angiographyFleur R de Graaf, Joëlla E van Velzen, Stephanie M de Boer, et al.
International Journal of Radiation Oncology, Biology, Physics|November 5, 2015
Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 TrialStephanie M de Boer, Remi A Nout, Ina M Jürgenliemk-Schulz, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 25, 2022
p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trialLisa Vermij, Alicia Léon-Castillo, Naveena Singh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2023
Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial CancerNanda Horeweg, Remi A Nout, Ina M Jürgenliemk-Schulz, et al.
The Lancet. Oncology|July 12, 2016
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
British Journal of Cancer|January 23, 2023
Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistryLisa Vermij, Jan J Jobsen, Alicia León-Castillo, et al.
Clinical and Translational Radiation Oncology|February 12, 2026
Dynamic immune changes after bone marrow sparing VMAT in women with locally advanced cervical cancer treated with chemoradiotherapyAnouk Corbeau, Marij J P Welters, Sanne Boekestijn, et al.
Nature Communications|March 17, 2022
Tertiary lymphoid structures critical for prognosis in endometrial cancer patientsNanda Horeweg, Hagma H Workel, Dominik Loiero, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 8, 2024
Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter HypermethylationMerve Kaya, Cathalijne C B Post, Carli M Tops, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
The American Journal of Cardiology|November 9, 2010
Impact of clinical presentation and pretest likelihood on the relation between calcium score and computed tomographic coronary angiographyJacob M van Werkhoven, Stephanie M de Boer, Joanne D Schuijf, et al.
The International Journal of Cardiovascular Imaging|May 12, 2012
Non-invasive computed tomography coronary angiography as a gatekeeper for invasive coronary angiographyFleur R de Graaf, Joëlla E van Velzen, Stephanie M de Boer, et al.
International Journal of Radiation Oncology, Biology, Physics|November 5, 2015
Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 TrialStephanie M de Boer, Remi A Nout, Ina M Jürgenliemk-Schulz, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 25, 2022
p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trialLisa Vermij, Alicia Léon-Castillo, Naveena Singh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2023
Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial CancerNanda Horeweg, Remi A Nout, Ina M Jürgenliemk-Schulz, et al.
The Lancet. Oncology|July 12, 2016
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
British Journal of Cancer|January 23, 2023
Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistryLisa Vermij, Jan J Jobsen, Alicia León-Castillo, et al.
Clinical and Translational Radiation Oncology|February 12, 2026
Dynamic immune changes after bone marrow sparing VMAT in women with locally advanced cervical cancer treated with chemoradiotherapyAnouk Corbeau, Marij J P Welters, Sanne Boekestijn, et al.
Nature Communications|March 17, 2022
Tertiary lymphoid structures critical for prognosis in endometrial cancer patientsNanda Horeweg, Hagma H Workel, Dominik Loiero, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 8, 2024
Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter HypermethylationMerve Kaya, Cathalijne C B Post, Carli M Tops, et al.
Pageof 4